证券代码：605033 证券简称：美邦股份 公告编号：2023-078 项目合伙人：王彩霞，2011年成为中国注册会计师，2011年开始从事上市公 司审计业务，2009年开始在容诚会计师事务所执业，2023年开始为公司提供审计 服务；近三年签署过容知日新（688768. SH）、合锻智能（603011.SH）、悦康药 业（688658.SH）等多家上市公司审计报告。 陕西美邦药业集团股份有限公司 关于更换签字会计师的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 陕西美邦药业集团股份有限公司（以下简称"公司"或"美邦股份"）分别 于2023年4月18日、2023年5月17日召开第二届董事会第二十一次会议、2022年年 度股东大会，审议通过了《关于公司聘用会计师事务所的议案》，同意公司聘请 容诚会计师事务所(特殊普通合伙)（以下简称"容诚会计师事务所"）为公司 2023年度财务报表审计和内部控制审计的会计师事务所。具体内容详见公司于 2023年4月20日在上海证券交易所网站披露的《陕西美邦药业集团股份有限公司关 于公 ...

2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：605033 证券简称：美邦股份 公告编号：2023-077 陕西美邦药业集团股份有限公司 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事会召集，以现场投票和网络投票相结合的方式进行表决， (一) 股东大会召开的时间：2023 年 12 月 22 日 (二) 股东大会召开的地点：陕西省西安市经济技术开发区草滩三路石羊工业 园区 A19 号楼陕西美邦药业集团股份有限公司三楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 会议由董事长张少武先生主持。本次会议的召集、召开程序符合《公司法》及《公 司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事 9 人，出席 9 人； 二、 议案审议情况 | 1、出席会议的股东和代理人人数 | 16 | | --- | --- ...

国浩律师（上海）事务所 关 于 陕西美邦药业集团股份有限公司 2023 年第二次临时股东大会 的 法律意见书 上海市北京西路 968 号嘉地中心 23-25、27 层 邮编：200041 23-25,27/F, Garden Square, No. 968 West Beijing Road, Shanghai 200041, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 2023 年 12 月 国浩律师（上海）事务所 股东大会法律意见书 国浩律师（上海）事务所 关于陕西美邦药业集团股份有限公司 2023 年第二次临时股东大会的法律意见书 致：陕西美邦药业集团股份有限公司 陕西美邦药业集团股份有限公司（以下简称"公司"）2023 年第二次临时股东 大会于 2023 年 12 月 22 日 15 点在陕西省西安市经济技术开发区草滩三路石羊 工业园区 A19 号楼陕西美邦药业集团股份有限公司三楼会议室召开，国浩律师 （上海）事务所（以下简称"本所"）接受公司的委托，指派秦 ...

陕西美邦药业集团股份有限公司 二〇二三年第二次临时股东大会 会议资料 二〇二三年十二月 2023 年第二次临时股东大会会议资料 股票简称：美邦股份 股票代码：605033 2023 年第二次临时股东大会会议资料 会议须知 为确保陕西美邦药业集团股份有限公司（以下简称"本公司"或"公司"）股 东在本公司 2023 年第二次临时股东大会（以下简称"本次会议"）依法行使权利， 保证会议秩序和议事效率，相关事项如下： 一、公司根据《中华人民共和国公司法》《中华人民共和国证券法》《陕 西美邦药业集团股份有限公司章程》（以下简称"《公司章程》"）及《陕西美 邦药业集团股份有限公司股东大会议事规则》（以下简称"《股东大会议事规 则》"）规定，认真做好本次会议的各项工作。 二、公司董事会在本次会议过程中，应当认真履行法定职责，维护股东合 法权益。 三、公司股东出席本次会议，依法享有《公司章程》规定的各项权利，并 认真履行法定义务，不得侵犯其他股东的合法权益，不得扰乱本次会议的正常 秩序。 四、本次会议议案的表决采取现场记名投票与网络投票相结合的方式投票 表决。本次会议议案全部是采用非累积投票制进行投票：股东以其持有的有表 决 ...

证券代码：605033 证券简称：美邦股份 陕西美邦药业集团股份有限公司 投资者关系活动记录表 编号：2023-11-15 投资者关系活动 特定对象调研 分析师会议 类别 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他（请文字说明其他活动内容） 参与单位名称及 线上参与公司2023年第三季度业绩说明会的全体投资者 人员姓名 2023年11月15日 15:00-16:00 时间 价值在线（https://www.ir-online.cn/） 地点 董事长 张少武；独立董事 段又生；财务负责人 何梅喜； 上市公司接待人 员姓名 董事会秘书 赵爱香； 1.公司未来行业发展趋势有哪些特点，公司的主要竞争优势有哪些？ 答:尊敬的投资者，您好！行业发展趋势的主要特点：农药产业升级、 投资者关系活动 ...

陕西美邦药业集团股份有限公司 2023 年第三季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 证券代码：605033 证券简称：美邦股份 陕西美邦药业集团股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 同期增减变 | | | | 动幅度(%) | | 动幅度(%) | | 营业收入 | | | | | | | 77,486,805.40 | 16.74% ...

陕西美邦药业集团股份有限公司 2023 年半年度报告 公司代码：605033 公司简称：美邦股份 陕西美邦药业集团股份有限公司 2023 年半年度报告 1 / 172 陕西美邦药业集团股份有限公司 2023 年半年度报告 重要提示 本报告中涉及的未来发展计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，投资者 及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间的差异，请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 十、 重大风险提示 公司已在本报告中详细描述可能存在的相关风险，敬请查阅"第三节 管理层讨论与分析"中"其他 披露事项"中"可能面对的风险"部分的内容。 2 / 172 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 344,708,419.69, a decrease of 29.30% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 69,276,052.01, down 24.50% year-on-year[5]. - The basic earnings per share decreased to CNY 0.51, reflecting a decline of 24.50%[6]. - The company reported a net profit margin of 24.7% for Q1 2023, compared to 25.8% in Q1 2022[20]. - In Q1 2023, the company's net profit was CNY 69,276,052.01, a decrease of 24.6% compared to CNY 91,752,261.05 in Q1 2022[22]. - Operating profit for Q1 2023 was CNY 79,271,153.70, down from CNY 106,982,851.88 in the same period last year, reflecting a decline of 26.0%[22]. - The total profit for Q1 2023 was CNY 79,946,102.29, down from CNY 106,934,436.60 in Q1 2022, reflecting a decrease of 25.2%[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,437,247,389.95, a decrease of 7.90% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,437,247,389.95, down from RMB 1,560,494,842.26 at the end of 2022, a decrease of 7.9%[18]. - Total liabilities decreased to RMB 281,618,625.34 from RMB 474,142,129.66, a significant reduction of 40.7%[18]. - The equity attributable to shareholders increased to RMB 1,155,628,764.61 from RMB 1,086,352,712.60, an increase of 6.4%[19]. Cash Flow and Investments - Cash flow from operating activities was negative at CNY -62,936,566.19, indicating a significant cash outflow[5]. - The cash flow from operating activities in Q1 2023 was negative at CNY -62,936,566.19, an improvement from CNY -81,768,900.40 in Q1 2022[25]. - Investment activities generated a net cash outflow of CNY -2,593,704.84 in Q1 2023, compared to a net inflow of CNY 13,871,427.04 in Q1 2022[25]. - The company reported cash and cash equivalents at the end of Q1 2023 amounting to CNY 242,286,396.44, up from CNY 91,338,101.17 at the end of Q1 2022[26]. Receivables and Inventory - Accounts receivable increased by 62.84%, primarily due to the timing of customer settlements[10]. - Accounts receivable increased to RMB 302,507,518.83 from RMB 185,766,247.94, reflecting a growth of 62.9%[17]. - Inventory decreased to RMB 331,957,925.01 from RMB 457,288,782.73, a reduction of 27.4%[17]. Expenses and Cost Management - The company experienced a 54.50% reduction in selling expenses, reflecting cost-cutting measures[10]. - Total operating costs for Q1 2023 were RMB 259,802,086.69, down 28.2% from RMB 361,683,622.68 in Q1 2022[20]. - Research and development expenses in Q1 2023 were CNY 19,925,881.93, a decrease of 22.3% from CNY 25,662,200.89 in Q1 2022[22]. - The company incurred sales expenses of CNY 21,956,508.77 in Q1 2023, compared to CNY 48,255,591.69 in Q1 2022, indicating a reduction of 54.4%[22]. Future Outlook - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[20].

Financial Performance - The company's operating revenue for 2022 was CNY 906,045,600.11, representing a year-on-year increase of 7.54% compared to CNY 842,490,330.97 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 145,088,329.38, an increase of 15.38% from CNY 125,742,881.24 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 131.48 million, up 18.39% from the previous year[34]. - The basic earnings per share for 2022 was CNY 1.07, down 6.14% from CNY 1.14 in 2021[24]. - The weighted average return on equity decreased to 14.13%, down 6.48 percentage points from 20.61% in the previous year[24]. - The company reported a net profit of CNY 91,752,261.05 in the first quarter of 2022, with a significant drop in the third quarter resulting in a loss of CNY 5,200,157.13[26]. - The total net assets attributable to shareholders of the listed company increased to CNY 1,086,352,712.60, a rise of 12.35% from CNY 966,952,383.22 in 2021[23]. - The company maintained a total asset value of 1.56 billion yuan and net assets attributable to shareholders of 1.09 billion yuan[58]. - The company achieved operating revenue of 906.05 million yuan, a year-on-year increase of 7.54%[58]. - Net profit attributable to shareholders was 145.09 million yuan, up 15.38% compared to the previous year[58]. - The net cash flow from operating activities increased by 216.24%, amounting to CNY 126,411,753.13, primarily due to a decrease in raw material prices and reduced procurement expenditures[24]. Dividends and Shareholder Returns - The company plans to distribute cash dividends of 2.20 CNY per 10 shares, totaling 29,744,000 CNY for the year 2022[5]. - The cash dividend ratio accounts for 20.5% of the net profit attributable to shareholders of the listed company for the fiscal year 2022[181]. - The remaining undistributed profit amounts to CNY 443,399,115.99[177]. - The cash dividend distribution plan requires approval from the shareholders' meeting before implementation[177]. - The company has established a cash dividend policy that complies with its articles of association and shareholder resolutions[178]. - The independent directors have fulfilled their responsibilities regarding the cash dividend policy[178]. - The cash dividend distribution is fully funded from the company's undistributed profits[181]. - The company has proposed a three-year dividend return plan for shareholders from 2022 to 2024[148]. Research and Development - The company invested CNY 80.04 million in R&D, a 25.45% increase year-on-year, representing 8.83% of operating revenue[37]. - The company has established partnerships with several universities for research and development, focusing on new products in the fields of fungicides and insecticides[93]. - The company has achieved significant results in reducing waste emissions and improving production capacity and quality in pesticide formulation development[90]. - The company emphasizes the importance of technology innovation and has implemented various management systems to enhance R&D capabilities[92]. - The company plans to enhance its research and development capabilities by establishing a national-level technology center and a postdoctoral research station, focusing on new products and formulations to meet diverse market demands[123]. Market Position and Strategy - The company is constructing two key projects: a 30,000-ton new green pesticide formulation and water-soluble fertilizer production line, and a 20,000-ton pesticide raw material and intermediate production base[36]. - The company is focusing on the development of high-efficiency, low-toxicity pesticide products in response to national policies promoting green agriculture[79]. - The company has established itself as a leading enterprise in the pesticide formulation industry, recognized as a key agricultural industrialization leading enterprise in Shaanxi Province[86]. - The company has been ranked among the top 20 in China's pesticide industry formulation sales for four consecutive years, placing 15th in 2022[86]. - The company aims to enhance its competitiveness and profitability through continuous innovation and product updates[49]. - The company plans to deepen its presence in the pesticide market, leveraging successful marketing experiences and expanding its marketing network to enhance brand influence and market penetration[125]. Environmental and Sustainability Initiatives - The company is responding to national low-carbon policies and focusing on sustainable development through energy-saving and emission-reduction initiatives[39]. - The company is committed to environmental sustainability by developing efficient, low-toxicity pesticide formulations that align with market trends[130]. - The company achieved compliance with emission standards for both waste gas and wastewater during the reporting period, with average waste gas pollutant concentrations of VOC at 6.85 mg/m³ and COD in wastewater at 149.3 mg/L[194]. - The company has a valid pollution discharge permit until December 27, 2025, issued by the Weinan Ecological Environment Bureau, with major pollutants including waste gas and wastewater[193]. - The company conducted an emergency drill for environmental incidents during the reporting period, with the plan reviewed and filed with the local environmental bureau[197]. Corporate Governance and Management - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[138]. - The board of directors convened 11 meetings, with independent directors providing independent opinions on major decisions[140]. - The company has established an investor relations management system to ensure timely and accurate communication with investors[144]. - The company has implemented a restricted stock incentive plan to align the interests of management with shareholders[150]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.74 million yuan[158]. - Zhang Shaowu resigned as General Manager due to work adjustments, and Zhang Tong was appointed as the new General Manager effective July 18, 2022[159]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company aims to establish a robust risk management framework to ensure compliance and operational efficiency while enhancing overall safety and quality standards[128]. - The company has implemented measures to mitigate raw material price risks, including centralized purchasing during price increases and enhancing supplier relationships[131]. - The company has not experienced any major safety or environmental incidents but acknowledges potential risks from equipment failures or operational issues[135].

证券代码：605033 证券简称：美邦股份 编号：2022 -05-10 陕西美邦药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐ 分析师会议 | | 投资者关系 | ☐ 媒体采访 | 业绩说明会 | | 活动类别 | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 | | | | ☐ | 其他（请文字说明其他活动内容） | | 形式 | ☐ 现场 网上 | ☐ 电话会议 | | 参与单位名称 及人员姓名 | 2021 | 年度业绩说明会暨现金分红说明会线上参加人员 | | 时间 | 2022 年 05 月 10 日 | 15:00-16:00 | | 地点 | 价值在线（ www.i ...